188 related articles for article (PubMed ID: 38311733)
1. ANGPTL4 regulates ovarian cancer progression by activating the ERK1/2 pathway.
Xu J; Wu F; Zhu Y; Wu T; Cao T; Gao W; Liu M; Qian W; Feng G; Xi X; Hou S
Cancer Cell Int; 2024 Feb; 24(1):54. PubMed ID: 38311733
[TBL] [Abstract][Full Text] [Related]
2. ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.
Li YK; Gao AB; Zeng T; Liu D; Zhang QF; Ran XM; Tang ZZ; Li Y; Liu J; Zhang T; Shi GQ; Zhou WC; Zou WD; Peng J; Zhang J; Li H; Zou J
J Transl Med; 2024 Jan; 22(1):46. PubMed ID: 38212795
[TBL] [Abstract][Full Text] [Related]
3. Deregulation of angiopoietin-like 4 slows ovarian cancer progression through vascular endothelial growth factor receptor 2 phosphorylation.
Wu Y; Gao J; Liu X
Cancer Cell Int; 2021 Mar; 21(1):171. PubMed ID: 33726754
[TBL] [Abstract][Full Text] [Related]
4. ANGPTL4 functions as an oncogene through regulation of the ETV5/CDH5/AKT/MMP9 axis to promote angiogenesis in ovarian cancer.
Liu Y; Yang R; Zhang Y; Zhu Y; Bao W
J Ovarian Res; 2022 Dec; 15(1):131. PubMed ID: 36517864
[TBL] [Abstract][Full Text] [Related]
5. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
6.
Guo W; Sun Z; Zhao N; Zhou Y; Ren J; Huang L; Ping Y
Ann Transl Med; 2021 Nov; 9(22):1669. PubMed ID: 34988178
[TBL] [Abstract][Full Text] [Related]
7. microRNA-1271-5p/TIAM1 suppresses the progression of ovarian cancer through inactivating Notch signaling pathway.
Han FJ; Li J; Shen Y; Guo Y; Liu YC; Yu Y; Xu JY; Liu SX; Wang YH
J Ovarian Res; 2020 Sep; 13(1):110. PubMed ID: 32948241
[TBL] [Abstract][Full Text] [Related]
8. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.
Wu Y; Wang T; Xia L; Zhang M
Cancer Cell Int; 2021 May; 21(1):284. PubMed ID: 34051810
[TBL] [Abstract][Full Text] [Related]
9. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
10. Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44/CD117 in human ovarian cancer SKOV3 cells.
Fan Y; Cheng H; Liu Y; Liu S; Lowe S; Li Y; Bentley R; King B; Tuason JPW; Zhou Q; Sun C; Zhang H
Front Pharmacol; 2022; 13():955984. PubMed ID: 36046821
[No Abstract] [Full Text] [Related]
11. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
[TBL] [Abstract][Full Text] [Related]
12. Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway.
Liu H; Shi H; Fan Q; Sun X
Tumour Biol; 2016 Aug; 37(8):10161-75. PubMed ID: 26831658
[TBL] [Abstract][Full Text] [Related]
13. TPX2 gene silencing inhibits cell proliferation and promotes apoptosis through negative regulation of AKT signaling pathway in ovarian cancer.
Tian Y; Liu LL; Guo DM; Wang Y; Zha WH; Li Y; Wu FJ
J Cell Biochem; 2018 Sep; 119(9):7540-7555. PubMed ID: 29904936
[TBL] [Abstract][Full Text] [Related]
14. Angiopoietin-like 4 confers resistance to hypoxia/serum deprivation-induced apoptosis through PI3K/Akt and ERK1/2 signaling pathways in mesenchymal stem cells.
Hou M; Cui J; Liu J; Liu F; Jiang R; Liu K; Wang Y; Yin L; Liu W; Yu B
PLoS One; 2014; 9(1):e85808. PubMed ID: 24465718
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of cuproptosis-associated genes for predicting immunotherapy response in single-cell and multi-cohort studies.
Li H; Wang Y; Li G; Xiong J; Qin L; Wen Q; Yue C
J Gene Med; 2024 Jan; 26(1):e3600. PubMed ID: 37776237
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma.
Hu K; Babapoor-Farrokhran S; Rodrigues M; Deshpande M; Puchner B; Kashiwabuchi F; Hassan SJ; Asnaghi L; Handa JT; Merbs S; Eberhart CG; Semenza GL; Montaner S; Sodhi A
Oncotarget; 2016 Feb; 7(7):7816-28. PubMed ID: 26761211
[TBL] [Abstract][Full Text] [Related]
17. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
Yuan S; Xu Y; Yi T; Wang H
J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of long non‑coding RNA CCEPR is associated with poor prognosis and contributes to the progression of ovarian cancer through regulating the Wnt/β‑catenin signaling pathway.
Chen Z; Zhu Y; Fan X; Liu Y; Feng Q
Mol Med Rep; 2020 Apr; 21(4):1950-1958. PubMed ID: 32319633
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis.
Liu T; Shen J; He Q; Xu S
Front Genet; 2022; 13():814291. PubMed ID: 35237300
[TBL] [Abstract][Full Text] [Related]
20. TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis.
Li C; Wang Q; Luo Y; Xiang J
Anal Cell Pathol (Amst); 2022; 2022():5632164. PubMed ID: 36247876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
